Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470996) titled 'T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR' on March 10.

Study Type: Observational

Primary Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Condition: Peripheral T Cell Lymphoma

Intervention: Procedure: Allogenic stem cell transplant (ASCT)

Recruitment Status: Recruiting

Date of First Enrollment: October 1, 2025

Target Sample Size: 58

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07470996

Disclaimer: Curated by HT Syndication....